Collegium forecasts $65M-$75M from Azstarys and maintains Jornay PM revenue guidance at $190M-$200M for 2026.
Collegium Pharmaceutical outlined 2026 revenue targets for its ADHD portfolio, projecting $65M-$75M from Azstarys while keeping Jornay PM guidance steady at $190M-$200M. The company cited strong growth in its ADHD business during Q2 2026.
Jornay PM prescriptions rose 13.1% year-over-year, generating $46.1 million in net revenue, a 41% increase from the same period last year. Management attributed the gains to expanding market adoption and prescription trends.
The company did not disclose immediate market reactions to the guidance update, focusing instead on operational performance and long-term projections.